MK2

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Tuesday, February 27, 2024
Sun Pharma, Collection, MK2, Research, Eli Lilly and Company, ACRS, Atopic dermatitis, Health, Intangibles, Interim, IPR, Therapy, Rheumatoid arthritis, Patient, G&A, Pancreatic cancer, Pharmaceutical industry

Aclaris reported positive results from its Phase 1 MAD trial of ATI-2138 in September 2023.

Key Points: 
  • Aclaris reported positive results from its Phase 1 MAD trial of ATI-2138 in September 2023.
  • Net loss was $1.5 million for the fourth quarter of 2023 compared to $27.6 million for the fourth quarter of 2022.
  • Total revenue was $17.6 million for the fourth quarter of 2023 compared to $7.8 million for the fourth quarter of 2022.
  • Licensing expenses were $5.7 million for the quarter ended December 31, 2023 compared to $0.6 million for the prior year period.

Aclaris Therapeutics Provides Corporate Update

Retrieved on: 
Tuesday, December 19, 2023
Workforce, Atopic dermatitis, Osteoporosis, Therapy, Clinical trial, Pharmacokinetics, Kinect, Professional, MK2, Pancreatic cancer, Patient, Safety, ACRS, Ulcerative colitis, Pharmaceutical industry

WAYNE, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced several corporate updates.

Key Points: 
  • WAYNE, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced several corporate updates.
  • First, Aclaris announced the publication of the Phase 2a trial results of ATI-1777 in moderate to severe atopic dermatitis (AD) in the peer-reviewed journal JID Innovations on November 27, 2023.
  • Based on these results, Aclaris progressed ATI-1777 into a Phase 2b trial in patients with mild to severe AD.
  • Aclaris plans to use ATI-450 instead of ATI-2231, its second MK2 inhibitor, due to ATI-450’s more advanced clinical development package.

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Webcast, Pancreatic cancer, MK2, Safety, Therapy, Clinical trial, Patient, ACR20, Rheumatoid arthritis, ACRS, Pharmacokinetics, Ulcerative colitis, Atopic dermatitis, Topical medication, Toxic leukoencephalopathy, Osteoporosis, MTX, Pharmaceutical industry, Czech Republic

WAYNE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced top-line results from a Phase 2b study of zunsemetinib (ATI-450), an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis (RA; ATI-450-RA-202).

Key Points: 
  • The primary efficacy endpoint is the proportion of patients achieving an ACR20 response following 12 weeks of treatment.
  • Based on the overall program results, Aclaris will discontinue further development of the ATI-450 program, including halting enrollment of Aclaris’ ongoing Phase 2a trial of zunsemetinib in psoriatic arthritis.
  • “We are deeply disappointed with the results of this trial and for patients suffering from rheumatoid arthritis.
  • Aclaris is supporting Washington University in a first-in-human investigator-initiated Phase 1a trial of ATI-2231 in patients with advanced solid tumor malignancies.

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Monday, November 6, 2023
Janus, Research, Lilly, Eli Lilly and Company, AD, Plasma, Half-life, PD, Psoriatic arthritis, Washington University in St. Louis, Biomarker, JAK3, EPI, G&A, Health, Rheumatoid arthritis, MAD, JAK, R, RA, ITK, ACRS, Ulcerative colitis, Osteoporosis, Pharmacokinetics, Hidradenitis suppurativa, PK, Methotrexate, Pancreatic cancer, Safety, Atopic dermatitis, Collection, Chapter 11, Title 11, United States Code, Therapy, Patient, MK2, Pharmaceutical industry, Vaccine, Palladium, Cryptocurrency, Rare-earth element, Tobacco, Hydraulic machinery

WAYNE, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2023 and provided a corporate update.

Key Points: 
  • Net loss was $29.3 million for the third quarter of 2023 compared to $20.0 million for the third quarter of 2022.
  • Total revenue was $9.3 million for the third quarter of 2023 compared to $19.0 million for the third quarter of 2022.
  • Research and development (R&D) expenses were $23.9 million for the quarter ended September 30, 2023 compared to $23.7 million for the prior year period.
  • General and administrative (G&A) expenses were $7.1 million for the quarter ended September 30, 2023 compared to $5.8 million for the corresponding prior year period.

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Monday, August 7, 2023
Janus, PK, Psoriatic arthritis, EPI, RA, PD, Therapy, Half-life, Chapter 11, Title 11, United States Code, JAK, Health, Pharmacokinetics, Atopic dermatitis, Methotrexate, G&A, MK2, Washington University in St. Louis, Sale, Ulcerative colitis, Plasma, ACRS, ATM, Lilly, Patient, Collection, Rheumatoid arthritis, R, Research, AD, Safety, Pharmaceutical industry, Vaccine, Cryptocurrency, Video game, Rare-earth element, Tobacco, Hydraulic machinery

WAYNE, Pa., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2023 and provided a corporate update.

Key Points: 
  • Aclaris continues to expect topline data in the fourth quarter of 2023.
  • Aclaris continues to expect topline data in the second half of 2023.
  • Net loss was $29.6 million for the second quarter of 2023 compared to $20.5 million for the second quarter of 2022.
  • Total revenue was $1.9 million for the second quarter of 2023 compared to $1.5 million for the second quarter of 2022.

EQS-News: Mynaric optimizes management structure: Mustafa Veziroglu will become sole CEO with Bulent Altan set to join Supervisory Board

Retrieved on: 
Thursday, May 11, 2023
CONDOR, HAWK, Policy, Supervisory board, Lead, FRA, MK2, Supervision, SpaceX, Growth, Management, Mynaric

MUNICH, May 11, 2023 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective, and scalable laser communications products, today announced that the management and supervisory board jointly decided on a plan to further optimize the leadership structure of Mynaric.

Key Points: 
  • MUNICH, May 11, 2023 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective, and scalable laser communications products, today announced that the management and supervisory board jointly decided on a plan to further optimize the leadership structure of Mynaric.
  • Mustafa Veziroglu joined Mynaric’s management board in August 2022 and most recently served as Co-CEO of the company leading all operational product-related activities overseeing the entire product lifecycle from development through delivery.
  • His role as CEO will be to strengthen Mynaric’s focus on 2023 execution targets particularly with respect to production and positioning the company for long-term growth.
  • His role as part of the Supervisory Board will be to represent the company externally and to carry Mynaric’s vision of ubiquitous optical communications across the space industry.

Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera

Retrieved on: 
Tuesday, May 9, 2023
Biotechnology, Hospitals, Health, Pharmaceutical, Oncology, DNA, Gilead Sciences, IPR, HRD, Neoplasm, Cancer, Breast, MK2, Inflammation, Prostate, PARP1, Acquisition, Patient, Science, Financial toxicity, EPS, BRCA, Sacituzumab govitecan, Pharmaceutical industry, Research

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego.
  • The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation.
  • Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year.
  • We expect the transaction with XinThera to reduce Gilead’s GAAP and non-GAAP 2023 EPS by approximately $0.12 - $0.15.

Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Monday, May 8, 2023
Janus, PK, Psoriatic arthritis, RA, PD, Half-life, JAK, Pharmacokinetics, Atopic dermatitis, Methotrexate, G&A, MK2, Ulcerative colitis, Plasma, ACRS, ATM, Lilly, Hidradenitis suppurativa, Patient, Rheumatoid arthritis, Webcast, R, Research, AD, Therapy, Safety, Disease, Pharmaceutical industry, Bank, Video game

WAYNE, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2023 and provided a corporate update.

Key Points: 
  • WAYNE, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2023 and provided a corporate update.
  • Based on the continued positive enrollment momentum, Aclaris is narrowing its timing guidance for topline data to the fourth quarter of 2023.
  • As a result, Aclaris currently projects topline data in the second half of 2023, rather than mid-year 2023.
  • Net loss was $28.2 million for the first quarter of 2023 compared to $18.8 million for the first quarter of 2022.

EQS-News: Mynaric receives order from Loft Federal for CONDOR Mk3 optical communications terminals to support NExT – SDA’s Experimental Testbed

Retrieved on: 
Tuesday, May 2, 2023
Communication, CONDOR, SDA, Human, Northrop Grumman, SAR, Capella Space, Orbit, Telesat, Space Development Agency, Northrop, Grumman, FRA, Government, Sale, DARPA, MK2, NeXT, LOS, Surveying, Communications satellite, Mynaric, Longbow

LOS ANGELES, May 2, 2023 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective and scalable laser communications products, today announced that it entered into a definitive agreement for the sale of CONDOR Mk3 terminals to Loft Federal, a subsidiary of Loft Orbital .

Key Points: 
  • LOS ANGELES, May 2, 2023 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective and scalable laser communications products, today announced that it entered into a definitive agreement for the sale of CONDOR Mk3 terminals to Loft Federal, a subsidiary of Loft Orbital .
  • Loft Federal was selected to produce, deploy and operate NExT – the Space Development Agency's (SDA) Experimental Testbed and will use the terminals to support secure and reliable communications.
  • The order announced today was received in late 2022 and was already accounted for in the previously disclosed optical communications terminal backlog as of December 31, 2022.
  • “The CONDOR Mk3 terminal enables us to provide reliable performance on Longbow, our turnkey satellite platform,” said John Eterno, General Manager at Loft Federal.

Nauticus Robotics Announces Splashdown of Next Generation Aquanauts

Retrieved on: 
Thursday, April 13, 2023
Carbon footprint, Data collection, Intelligence, MK2, Aquanaut, Data analysis, Robotics, Gulf of Mexico, Artificial intelligence, Growth, Safety, Mobile phone, Nauticus

Following commissioning, Nauticus expects to send the initial Aquanaut MK2 units to the North Sea and the Gulf of Mexico in the coming months to support customer initiatives in those regions.

Key Points: 
  • Following commissioning, Nauticus expects to send the initial Aquanaut MK2 units to the North Sea and the Gulf of Mexico in the coming months to support customer initiatives in those regions.
  • The Aquanaut MK2 is a fully electric, untethered and autonomous subsea robot that is controlled through acoustic communication networking and underpinned by Nauticus’ proprietary software suite, toolKITT.
  • The artificial intelligence-based software suite allows for robotic controls, user interfaces, sensor integration, simulation, data analysis, and communication frameworks purpose-built to enable subsea work.
  • Aquanaut MK2’s defining capability is operating in two separate modes, actively transforming itself between the excursion and intervention configurations.